ZAS Ventures Invests in Ukrainian Startup Gamow Tech at €2.4M Valuation
Venture capital firm ZAS Ventures has invested in Gamow Tech, a Ukrainian startup developing software that uses artificial intelligence to improve the success rate of artificial insemination (AI) and in vitro fertilization (IVF) procedures. The company was valued at €2.4 million in the round, ZAS Ventures told Scroll.media.
- The amount of the deal has not been disclosed. According to the firm, the funding will be used to accelerate product development, complete multicenter clinical trials, and prepare for CE mark certification in the EU.
About Gamow Tech
- Gamow Tech is developing ReSpindle, an AI-powered tool designed to boost IVF success rates. The software uses computer vision to analyze female eggs and detect chromosomal abnormalities — a leading cause of declining fertility with age.
- According to ZAS Ventures, ReSpindle enables embryologists to perform fast, non-invasive, real-time assessments of egg viability. The technology is also significantly more affordable than traditional genetic testing methods.
«ReSpindle is paving the way for a breakthrough in women’s health and reproductive medicine. Their technology addresses one of the biggest challenges in IVF — identifying viable eggs before fertilization without invasive procedures. This aligns perfectly with our mission to support Ukrainian deep-tech founders building global solutions,» said Andrew Zinchuk, founder and managing partner of ZAS Ventures.
- Gamow Tech was founded by embryologist Pavlo Mazur (featured in the Netflix documentary Unnatural Selection about genetic engineering), Kostiantyn Hnennyi (former Forbes analyst with a master’s in biophysics), and Maksym Slyzkoukh, a serial deep-tech entrepreneur. Davyd Maiboroda (formerly of Reface) has joined the team as CTO.
- The company has already signed R&D agreements with nine leading IVF clinics, representing more than 1% of the global IVF market.
- Initial results from ReSpindle demonstrate both the scientific validity and commercial potential of the company’s technology in the €26 billion global IVF market.
ZAS Ventures Invests in Ukrainian Startup Gamow Tech at €2.4M Valuation
Venture capital firm ZAS Ventures has invested in Gamow Tech, a Ukrainian startup developing software that uses artificial intelligence to improve the success rate of artificial insemination (AI) and in vitro fertilization (IVF) procedures. The company was valued at €2.4 million in the round, ZAS Ventures told Scroll.media.
- The amount of the deal has not been disclosed. According to the firm, the funding will be used to accelerate product development, complete multicenter clinical trials, and prepare for CE mark certification in the EU.
About Gamow Tech
- Gamow Tech is developing ReSpindle, an AI-powered tool designed to boost IVF success rates. The software uses computer vision to analyze female eggs and detect chromosomal abnormalities — a leading cause of declining fertility with age.
- According to ZAS Ventures, ReSpindle enables embryologists to perform fast, non-invasive, real-time assessments of egg viability. The technology is also significantly more affordable than traditional genetic testing methods.
«ReSpindle is paving the way for a breakthrough in women’s health and reproductive medicine. Their technology addresses one of the biggest challenges in IVF — identifying viable eggs before fertilization without invasive procedures. This aligns perfectly with our mission to support Ukrainian deep-tech founders building global solutions,» said Andrew Zinchuk, founder and managing partner of ZAS Ventures.
- Gamow Tech was founded by embryologist Pavlo Mazur (featured in the Netflix documentary Unnatural Selection about genetic engineering), Kostiantyn Hnennyi (former Forbes analyst with a master’s in biophysics), and Maksym Slyzkoukh, a serial deep-tech entrepreneur. Davyd Maiboroda (formerly of Reface) has joined the team as CTO.
- The company has already signed R&D agreements with nine leading IVF clinics, representing more than 1% of the global IVF market.
- Initial results from ReSpindle demonstrate both the scientific validity and commercial potential of the company’s technology in the €26 billion global IVF market.